R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment

17th March 2026 Uncategorised 0

Financing and global licensing deal to accelerate phase 2b development of AP306

More: R1 Therapeutics launches with .5m to advance hyperphosphatemia treatment
Source: News